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Abstract Insulin receptor substrate-1 (IRS-1) and Shc protein
have the same binding site at the insulin receptor and compete in
their association with the phosphorylated receptor. The present
study demonstrates that a decrease in the level of muscle insulin
receptor phosphorylation induced by chronic growth hormone
(GH) treatment or acute epinephrine infusion is accompanied by
a reduction in the level of IRS-1 phosphorylation and in the
association with phosphatidylinositol 3-kinase. In contrast, no
change is observed in insulin-stimulated Shc tyrosine phospho-
rylation, or in the association of this substrate with Grb2. These
data suggest that a reduction in insulin receptor phosphorylation
may affect post-receptor processes differentially by preserving
the phosphorylation of some substrates and pathways, but not of
others.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The insulin receptor is the principal mediator of insulin
action in cellular mitogenic and metabolic processes. The in-
sulin receptor L-subunit, which contains an intrinsic tyrosine
kinase, undergoes tyrosyl autophosphorylation and is acti-
vated in response to insulin binding to the extracellular K-
subunit [1,2]. This interaction further enhances the tyrosine
kinase activity of the receptor towards other intermediate
molecules, including insulin receptor substrate-1 (IRS-1),
IRS-2 and Shc [3^9]. These molecules, rather than the insulin
receptor itself, then couple to a downstream signaling path-
way by serving as binding sites for SRO homology 2 (SH2)
domain-containing signaling molecules [10]. IRS-1 binds to
the 85 kDa subunit of phosphatidylinositol 3-kinase (PI 3-
kinase), Grb2 and other SH2-containing proteins [11]. Shc
protein has been shown to directly induce the association
with Grb2 [12]. Recent studies indicate that Shc and IRS-1
have the same binding site at the insulin receptor, a ¢nding
consistent with the suggestion that both Shc and IRS-1 com-
pete in their association with the phosphorylated receptor. As
yet, there has been no comparison of insulin-induced IRS-1
and Shc tyrosine phosphorylation in situations of insulin re-
sistance accompanied by a reduction in insulin receptor phos-
phorylation.
We have demonstrated elsewhere that there are common
molecular events in the muscle of rats treated chronically
with growth hormone (GH) [13] or acutely with epinephrine
[14], including a decrease in insulin-induced insulin receptor
and IRS-1 tyrosine phosphorylation and in the association of
the latter with PI 3-kinase. These reductions correlate with the
insulin resistance and reduced glucose uptake described in the
muscle of these animals [15,16]. In this study, we investigated
Shc and IRS-1 tyrosine phosphorylation in the muscle of the
above two animal models of insulin resistance, both of which
show reduced insulin-induced insulin receptor autophospho-
rylation.
2. Materials and methods
2.1. Materials
The reagents and apparatus for sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and immunoblotting were from
Bio-Rad (Richmond, CA, USA). Tris[hydroxymethyl]amino-methane
(Tris), phenylmethylsulfonyl £uoride (PMSF), aprotinin, silicone, and
dithiothreitol (DTT) were from Sigma Chemical Co. (St. Louis, MO,
USA). Sodium amobarbital and human recombinant insulin (Humu-
lin R) were from Lilly. Human biosynthetic GH (Norditropin) was
purchased from Novo Nordisk (Bagsvaerd, Denmark). [125I]Protein A
was from Amersham (Amersham, UK) and protein A Sepharose 6
MB from Pharmacia (Uppsala, Sweden). Nitrocellulose (BA85, 0.2
Wm) was from SchleicherpSchuell. Male Wistar rats were from the
UNICAMP Central Animal Breeding Center. Monoclonal antiphos-
photyrosine antibody (1 Wg/ml), polyclonal anti-Shc, polyclonal anti-
Grb2 and polyclonal anti-PI 3-kinase (p85) antibody were from Up-
state Biotechnology Incorporated (UBI, Lake Placid, NY, USA).
Anti-IRS-1 antibodies were raised in rabbits using a synthetic peptide
(Pep 80) derived from the amino acid sequence (YIPGATMGT-
SPALTGDEAA) corresponding to residues 489^507 of the rat protein
and puri¢ed by a⁄nity chromatography on a column prepared by
coupling the synthetic peptide to A⁄-Gel 10 (Bio-Rad Laboratories)
as previously described [17]. Anti-insulin receptor antibody was raised
in rabbits using a synthetic peptide derived from the amino acid
sequence (KKNGRILPRSNPS) corresponding to the C-terminus of
the rat protein [17].
2.2. Animals
Male Wistar rats, 6 weeks old, were divided into two groups and
the studies were performed in parallel using the control and treated
rats. All groups received standard rodent chow and water ad libitum.
An excess of GH was induced by the s.c. injection of human GH at a
dose of 1 mg twice a day for 5 days. The control group received the
equivalent amount of normal saline (0.9% NaCl). The experiments
were performed on the morning of the ¢fth day. In another series
of experiments, anesthetized rats were injected i.p. with epinephrine
(25 Wg/100 g body weight) or an equal volume of saline (control
group) and the animals used 5 min later. In all groups, the rats
were fasted for 12 h before being used as described below.
2.3. Methods
Rats were anesthetized with sodium amobarbital (15 mg/kg body
weight, i.p.), and were used 10^15 min later, i.e. as soon as anesthesia
was assured by the loss of pedal and corneal re£exes. The abdominal
cavity was opened, the vena cava exposed, and 6 Wg of insulin diluted
in normal saline (0.9% NaCl) was injected. Ninety seconds later, the
hindlimb muscle was removed, minced coarsely and homogenized
immediately in extraction bu¡er (1% Triton X-100, 100 mM Tris,
pH 7.4, containing 100 mM sodium pyrophosphate, 100 mM sodium
£uoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM PMSF and
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0.1 mg of aprotinin/ml) at 4‡C with a Polytron PTA 20S generator
(Brinkmann Instruments model PT 10/35) operated at maximum
speed for 30 s. For immunoprecipitation with anti-Shc, hindlimb
muscle was removed 5 min after the injection of insulin.
The extracts were centrifuged at 15 000 rpm and 4‡C in a Beckman
70.1 Ti rotor (Palo Alto, CA, USA) for 45 min to remove insoluble
material, and the resulting supernatant was used for immunoprecipi-
tation with anti-IRS-1, anti-Shc or anti-IR (insulin receptor) antibody
and protein A Sepharose 6 MB.
2.4. Protein analysis by immunoblotting
Proteins were denatured by boiling in Laemmli [18] sample bu¡er
containing 100 mM DTT, run on SDS-PAGE and transferred to
nitrocellulose membranes in Towbin [19] bu¡er containing 0.02%
SDS and 20% methanol. The membranes were blocked, probed, and
developed as described previously [20]. Blots were exposed to pre-
£ashed Kodak XAR ¢lm with Cronex Lightning Plus intensifying
screens at 380‡C for 12^48 h. Band intensities were quantitated by
optical densitometry (Hoefer Scienti¢c Instruments, San Francisco,
CA; model GS 300) of the developed autoradiographs that were
used at exposures in the linear range.
2.5. Statistical analysis
The experiments were performed by studying all groups of animals
in parallel. For comparisons, Student’s unpaired t-test was used as
appropriate. The level of signi¢cance employed was P6 0.05.
3. Results
3.1. Animal characteristics
Seven animals from each group of rats underwent an insu-
lin tolerance test. The glucose disappearance rate (Kitt) of the
control group was 4.40 þ 0.39%/min. Chronic GH treatment
and acute epinephrine treatment induced similar levels of in-
sulin resistance, as re£ected in their glucose disappearance
rates which were 1.94 þ 0.81%/min and 1.89 þ 0.63%/min, re-
spectively. Both of these values were signi¢cantly (P6 0.05)
lower that the control Kitt.
3.2. Characteristics of insulin-stimulated insulin receptor,
IRS-1 and Shc phosphorylation in the hindlimb muscle
of GH-treated rats
There was no change in the insulin receptor level of muscle
from rats treated with GH, as determined by immunoblotting
with an antibody to the COOH-terminus of the insulin recep-
tor (Fig. 1A). In muscle samples previously immunoprecipi-
tated with anti-insulin receptor antibody and immunoblotted
with antiphosphotyrosine antibody, there was a decrease to
43 þ 11% (P6 0.05, n = 6) in the insulin-stimulated phospho-
rylation of the 95 kDa L-subunit of the insulin receptor in
GH-treated rats when compared to the controls (Fig. 1B).
Using a speci¢c anti-peptide antibody against IRS-1, the
level of this protein was found to be unchanged in the muscle
of rats treated chronically with GH (Fig. 2A), although there
were changes in the level of phosphorylation of this protein
(Fig. 2B). Following the administration of insulin, the inten-
sity of this band increased in both groups of rats. However,
comparison of the bands stimulated by insulin revealed that
the extent of IRS-1 phosphorylation was reduced to 38 þ 11%
(P6 0.05, n = 6) in GH-treated rats compared to the controls.
Previous studies [6,10,21^24] have suggested that there is a
relatively stable, high a⁄nity interaction between IRS-1 and
the 85 kDa subunit of PI 3-kinase such that both proteins can
be co-precipitated by antibodies to either protein. In muscle
samples previously immunoprecipitated with anti-IRS-1 anti-
body and immunoblotted for the 85 kDa subunit of PI 3-
kinase (Fig. 2C), there was little basal PI 3-kinase immunore-
activity in the control and GH-treated rats. After stimulation
with insulin, a band with the expected molecular mass (85
kDa) of the PI 3-kinase regulatory subunit was observed in
anti-IRS-1 antibody immunoprecipitates of muscle from rats
in both groups. This ¢nding is consistent with a stable asso-
ciation between IRS-1 and PI 3-kinase. However, the amount
of PI 3-kinase associated with IRS-1 was reduced to 45 þ 7%
(P6 0.05, n = 4) in GH-treated rats, thus suggesting a dimin-
ished association between IRS-1 and PI 3-kinase. This reduc-
tion was probably a consequence of reduced IRS-1 tyrosyl
phosphorylation since the level of PI 3-kinase did not change
after GH treatment.
Chronic GH treatment did not signi¢cantly change the level
of Shc protein (Fig. 2D). To de¢ne better the extent of Shc
phosphorylation, we performed a Western blot analysis of
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Fig. 1. Insulin-stimulated tyrosine phosphorylation of the insulin re-
ceptor in muscle from GH-treated rats. Saline (0.9%, lanes 1 and 3
or insulin 6 Wg, lanes 2 and 4) was administered into the portal vein
as a bolus injection and 90 s later the muscle was excised and ali-
quots containing the same amount of protein were immunoprecipi-
tated with anti-insulin receptor antibody and immunoblotted with
the same antibody (A). The same samples were immunoprecipitated
with anti-insulin receptor antibody and immunblotted with anti-
phosphotyrosine antibody. (B) Scanning densitometry of autoradio-
grams was performed in six experiments. The black bars represent
the control group and the white bars represent the GH-treated
group. The data are expressed as the mean þ S.E.M. *P6 0.05.
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tyrosyl-phosphorylated proteins in anti-Shc immunoprecipi-
tates before and after stimulation with insulin in both groups
of animals. Basal Shc phosphorylation was higher in GH-
treated rats (138 þ 7%, P6 0.05, n = 4) than in the control
group. After stimulation with insulin, the intensity of this
band increased in both groups of animals, although the extent
of Shc phosphorylation in GH-treated rats was not signi¢-
cantly di¡erent from that in the controls (Fig. 2E). Since
Shc can associate with Grb2, after insulin stimulation, blots
with samples which had been previously immunoprecipitated
with anti-Shc were incubated with anti-Grb2 and no change
was observed in this association (Fig. 2F).
3.3. Characteristics of insulin-stimulated insulin receptor,
IRS-1 and Shc phosphorylation in the muscle of
epinephrine-treated rats
As in the rats treated with GH, acute epinephrine treatment
did not signi¢cantly change the insulin receptor protein level
(Fig. 3A). However, following stimulation with insulin, phos-
phorylation of the insulin receptor was reduced to 47 þ 4%
(P6 0.001, n = 6) in epinephrine-treated rats compared to
the controls (Fig. 3B).
Similarly, no signi¢cant change occurred in the level of
IRS-1 protein in the muscle of rats treated with epinephrine
when compared to the controls (Fig. 4A). To de¢ne better the
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Fig. 2. Insulin-stimulated tyrosine phosphorylation of IRS-1 and Shc in intact muscle from GH-treated rats. Saline (0.9%, lanes 1 and 3 or in-
sulin 6 Wg, lanes 2 and 4) was administered into the portal vein as a bolus injection and 90 s later the muscle was excised and aliquots contain-
ing the same amount of protein were immunoprecipitated with anti-IRS-1 and immunoblotted with the same antibody (A). The same samples
were immunoprecipitated with anti-IRS-1 antibody and immunoblotted with antiphosphotyrosine antibody (B). C: The immunoblotting results
of PI 3-kinase in anti-IRS-1 immunoprecipitates from the muscle of control and GH-treated rats. Five minutes after the bolus injection of sal-
ine or insulin (6 Wg), the muscle was excised and aliquots immunoprecipitated with anti-Shc antibody and blotted with the same antibody (D).
The same samples were immunoprecipitated with anti-Shc antibody and blotted with antiphosphotyrosine antibody (E). F: The immunoblotting
results of Grb2 in anti-Shc immunoprecipitates from the muscle of control and GH-treated rats. Scanning densitometry of autoradiograms was
performed in six experiments. The black bars represent the control group and the white bars represent the GH-treated group. The data are ex-
pressed as the mean þ S.E.M. *P6 0.05.
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level of IRS-1 phosphorylation, we performed a Western blot
analysis of the tyrosyl-phosphorylated proteins in anti-IRS-1
immunoprecipitates before and after stimulation with insulin
in both groups of animals. Fig. 4B shows that there was a
marked reduction to 53 þ 10% (P6 0.001, n = 9) in insulin-
stimulated IRS-1 phosphorylation in the muscle of animals
pretreated with epinephrine. To examine the association of
the 85 kDa subunit of PI 3-kinase with IRS-1, blots of sam-
ples which had been previously immunoprecipitated with anti-
IRS-1 antibodies were incubated with anti-PI 3-kinase anti-
body. As expected, in both groups an 85 kDa band was
present in the IRS-1 immunoprecipitates after exposure to
insulin and there was a decrease to 41 þ 8% (P6 0.001,
n = 4) in the intensity of this band in epinephrine-treated
rats (Fig. 4C).
Acute epinephrine treatment had no e¡ect on the Shc pro-
tein level in muscle as determined by immunoblotting of cell
lysates with anti-Shc antibody (Fig. 4D). In samples from
muscle previously immunoprecipitated with anti-Shc antibody
and immunoblotted with anti-phosphotyrosine antibody,
there was no change in insulin-stimulated Shc tyrosine phos-
phorylation in epinephrine-treated rats when compared to the
controls (Fig. 4E). Similarly, no change was observed in the
association between Shc/Grb2 when rats treated with epi-
nephrine were compared with controls (Fig. 4F).
4. Discussion
Following insulin stimulation, several proteins undergo ty-
rosine phosphorylation, including the L chain of the insulin
receptor, IRS-1, IRS-2 and Shc proteins [25]. We analyzed the
insulin-induced phosphorylation of these signaling intermedi-
ates in the muscle of rats treated chronically with GH and in
rats receiving an acute infusion of epinephrine. Insulin resist-
ance in these animals was demonstrated by a decrease in the
glucose disappearance rate after insulin infusion [13]. We ob-
served a reduction in insulin receptor and IRS-1 tyrosine
phosphorylation and also in the PI 3-kinase association with
IRS-1 in the muscle of both treated groups. These alterations
in the three early steps of insulin action may explain some
aspects of the insulin resistance observed in both of these
models since these steps seems to have an important role in
glucose homeostasis. Previous studies demonstrated that mice
homozygous for target disruption of the IRS-1 gene were
resistant to the glucose-lowering e¡ects of insulin [5,6], and
this correlated with a marked reduction in insulin-stimulated
glucose transport in isolated adipocytes [6]. Distinct experi-
mental approaches have also demonstrated a correlation be-
tween PI 3-kinase activity and glucose transport [26^28] and
PI 3-kinase activity and glycogen metabolism [28]. Thus, it
seems reasonable to speculate that the IRS-1/PI 3-kinase path-
way may be linked to the activation of glucose transport and
to glycogen synthesis in the muscle, and that a reduction in
these associations in both models may have a role in the
resulting insulin resistance.
Despite the reduction in insulin-stimulated tyrosine phos-
phorylation of the insulin receptor and IRS-1, no change was
observed in the tyrosine phosphorylation of Shc. After insu-
lin-induced Shc phosphorylation, Shc associates with the SH2
domain of the adapter protein Grb2 [29]. This association
induces Grb2 to bind to the nucleotide exchange factor
SOS, which in turn associates with and activates the GTP
binding protein p21Ras. This pathway has been implicated
in the mitogenic e¡ects of insulin [12,30]. Although Ras is
an upstream activator of the mitogen-associated protein kin-
ase (MAPK) cascade, recent evidence has shown that stimu-
lation of the MAPK pathway by insulin is not required for
many of the metabolic activities of the hormone in cultured
fat and muscle cells such as glucose uptake and glycogen syn-
thesis [31]. These results are in accordance with our ¢ndings
since in both animal models of insulin resistance we observed
a marked decrease in the glucose disappearance rate that par-
alleled a decrease in IRS-1 phosphorylation and association
with PI 3-kinase, but not Shc tyrosine phosphorylation. It is
interesting that the 60% reduction in IRS-1/PI 3-kinase asso-
ciation in both models was quite similar to the 60% reduction
in glucose disappearance rate observed in the two cases.
The dissociation of insulin-induced IRS-1 and Shc tyrosine
phosphorylation has been described in cell lines with muta-
tions at two tyrosine phosphorylation sites (Y1158, Y1162F,
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Fig. 3. Insulin-stimulated tyrosine phosphorylation of insulin recep-
tor in intact muscle from epinephrine-treated rats. Saline (0.9%,
lanes 1 and 3 or insulin 6 Wg, lanes 2 and 4) was administered into
the portal vein as a bolus injection and 90 s later the muscle was
excised and aliquots containing the same amount of protein were
immunoprecipitated with anti-insulin receptor antibody and immu-
noblotted with the same antibody (A). The same samples were im-
munoprecipitated with anti-insulin receptor antibody and immun-
blotted with anti-phosphotyrosine antibody (B). Scanning
densitometry of autoradiograms was performed in six experiments.
The black bars represent the control group and the white bars rep-
resent the epinephrine-treated group. The data are expressed as the
mean þ S.E.M. *P6 0.05.
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Y1163F-YFF) on the insulin receptor [32]. Such cell lines
showed insulin-induced tyrosine phosphorylation of Shc,
Shc-Grb2 complex formation, and p21Ras-GTP formation,
but had a reduced tyrosine phosphorylation of IRS-1 as
well as a reduced IRS-1 association with Grb2 and PI 3-kin-
ase [32]. These results, together with our own, suggest that a
reduction in insulin receptor phosphorylation may di¡eren-
tially induce post-receptor processes by preserving the phos-
phorylation of some substrates and pathways, but not that of
others. A dissociation between IRS-1 and Shc tyrosine phos-
phorylation without any change in insulin receptor level has
also been observed after treatment with dexamethasone [33] or
wortmannin [34].
The mechanism by which a reduction in insulin receptor
phosphorylation di¡erentially regulates its own substrates is
unknown. Shc can directly associate with the insulin receptor,
by a binding site to phosphorylated Tyr-960 in the receptor’s
juxtamembrane region [35]. This is the same binding site for
IRS-1 [36], and is consistent with the suggestion that both Shc
and IRS-1 compete for this tyrosine residue in their associa-
tion with the phosphorylated receptor [37]. Although IRS-1 is
best known as a substrate for tyrosine phosphorylation, it is
mainly a phosphoserine-containing protein. IRS-1 contains
over 30 potential serine/threonine phosphorylation sites in
motifs recognized by various kinases such as PKC, MAP kin-
ases and cyclic AMP- and cyclic GMP-dependent protein kin-
ases [25,38,39]. Serine phosphorylation also plays a role in the
regulation of IRS-1 signalling. Okadaic acid, a serine phos-
phatase inhibitor, increases serine phosphorylation of IRS-1
in 3T3-L1 adipocytes and this appears to inhibit insulin-
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Fig. 4. Insulin-stimulated tyrosine phosphorylation of insulin receptor and Shc in intact muscle from epinephrine-treated rats. Saline (0.9%,
lanes 1 and 3 or insulin 6 Wg, lanes 2 and 4) was administered into the portal vein as a bolus injection and 90 s later the muscle was excised
and aliquots containing the same amount of protein were immunoprecipitated with anti-insulin IRS-1 and immunoblotted with the same anti-
body (A). The same samples were immunoprecipitated with anti-IRS-1 antibody and immunoblotted with antiphosphotyrosine antibody (B). C:
The immunoblotting results of PI 3-kinase in anti-IRS-1 immunoprecipitates from the muscle of control and GH-treated rats. Five minutes
after the bolus injection of saline or insulin (6 Wg), the muscle was excised and aliquots were immunoprecipitated with anti-Shc antibody and
blotted with the same antibody (D). The same samples were immunoprecipitated with anti-Shc antibody and blotted with antiphosphotyrosine
antibody (E). F: The immunoblotting results of GRB2 in anti-Shc immunoprecipitates from the muscle of control and epinephrine-treated rats.
Scanning densitometry of autoradiograms was performed in six experiments. The black bars represent the control group and the white bars
represent the GH-treated group. The data are expressed as the mean þ S.E.M. *P6 0.05.
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stimulated tyrosine phosphorylation [40]. Thus, it is possible
that serine phosphorylation of IRS-1 (induced by chronic GH
treatment and/or hyperinsulinemia in one model and by an
increase in intracellular cAMP levels following exposure to
epinephrine in another) may reduce this substrate’s a⁄nity
for the insulin receptor, allowing Shc to be more competitive.
In support of this hypothesis, Li and Goldstein [34] have
recently shown that reducing IRS-1 serine phosphorylation
results in increased insulin-induced IRS-1 tyrosine phospho-
rylation and decreased Shc tyrosine phosphorylation.
Accelerated dephosphorylation of the insulin receptor and
IRS-1 by tyrosine phosphatases cannot be excluded in these
models of insulin resistance. In this regard, Wilson and Kacz-
marek [41] have demonstrated that an increase in cellular
cAMP through the activation of PKA increases the activity
of endogenous PTPase, thereby leading to a sequence of de-
phosphorylation.
A further interesting ¢nding in GH-treated rats was the
increase in basal Shc tyrosine phosphorylation without any
change in basal IRS-1 tyrosine phosphorylation. This increase
in phosphorylation may be related to the hormonal milieu of
these animals. There is evidence that GH can induce Shc
tyrosine phosphorylation in cultured cells [42] and in animal
tissues [43]. It is therefore possible that GH, hyperinsulinemia
and/or high serum levels of IGF-1 in the animals we studied
could preferentially induce Shc tyrosine phosphorylation to
the detriment of IRS-1 tyrosine phosphorylation for the
same reasons as those discussed above.
We have shown that chronic GH or acute epinephrine treat-
ment can speci¢cally decrease insulin-induced IRS-1 tyrosine
phosphorylation and association with PI 3-kinase. This may
help to explain the insulin resistance of these animals. In
muscle, both chronic GH treatment and the acute administra-
tion of epinephrine preserve insulin-induced Shc tyrosine
phosphorylation. Further investigation of the hormonal regu-
lation of the distinct signaling pathways activated by insulin
receptors will contribute to our understanding of the mecha-
nisms involved in this phenomenon.
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